Iovance Biotherapeutics (IOVA) Cash & Equivalents (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Cash & Equivalents of $196.5 million for Q1 2026, up 14.47% year-over-year from $171.7 million in Q1 2025, and up 20.5% quarter-over-quarter from $163.1 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Cash & Equivalents (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Cash & Equivalents for 16 consecutive years, with $196.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 14.47% year-over-year to $196.5 million; the TTM figure through Mar 2026 stood at $196.5 million (up 14.47% YoY), while the FY2025 annual figure was $163.1 million, up 40.96% from the prior year.
- Cash & Equivalents grew to $196.5 million in Q1 2026 per IOVA's latest filing, from $163.1 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $543.5 million in Q1 2023 and bottomed at $92.4 million in Q1 2022.
- Historically, Cash & Equivalents has averaged $186.5 million across 5 years, with a median of $163.1 million in 2025.
- Annual changes were most pronounced in 2023 — Cash & Equivalents surged 488.44% — and 2024, when it slumped 75.31%.
- Iovance Biotherapeutics' Cash & Equivalents stood at $231.7 million in 2022, then slumped by 50.42% to $114.9 million in 2023, then rose by 0.7% to $115.7 million in 2024, then soared by 40.96% to $163.1 million in 2025, then advanced by 20.5% to $196.5 million in 2026.
- Business Quant data shows IOVA's Cash & Equivalents at $196.5 million in Q1 2026, $163.1 million in Q4 2025, and $158.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 110.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 110.80 Mn |
| Mar 31, 2026 | 196.51 Mn |
| Dec 31, 2025 | 163.08 Mn |
| Sep 30, 2025 | 158.10 Mn |
| Jun 30, 2025 | 132.50 Mn |
| Mar 31, 2025 | 171.67 Mn |
| Dec 31, 2024 | 115.69 Mn |
| Sep 30, 2024 | 164.19 Mn |
| Jun 30, 2024 | 228.68 Mn |
| Mar 31, 2024 | 134.19 Mn |
| Dec 31, 2023 | 114.89 Mn |
| Sep 30, 2023 | 267.70 Mn |
| Jun 30, 2023 | 230.00 Mn |
| Mar 31, 2023 | 543.48 Mn |
| Dec 31, 2022 | 231.73 Mn |
| Sep 30, 2022 | 118.37 Mn |
| Jun 30, 2022 | 108.08 Mn |
| Mar 31, 2022 | 92.36 Mn |
| Dec 31, 2021 | 78.23 Mn |
| Sep 30, 2021 | 58.59 Mn |